{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:33:30Z","timestamp":1760369610203},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T00:00:00Z","timestamp":1586044800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T00:00:00Z","timestamp":1586044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00259-020-04796-w","type":"journal-article","created":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T10:02:32Z","timestamp":1586080952000},"page":"2633-2638","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223"],"prefix":"10.1007","volume":"47","author":[{"given":"Orazio","family":"Caffo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Frantellizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Monari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Baldari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Masini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bortolus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Facchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierpaolo","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Agostini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clizia","family":"Zichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Biasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelina","family":"Filice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Borsatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Spada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"De Vincentis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,5]]},"reference":[{"key":"4796_CR1","first-page":"293","volume":"1","author":"C Huggins","year":"1941","unstructured":"Huggins C, Hodges C. Studies on prostatic cancer, I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293\u20137.","journal-title":"Cancer Res"},{"key":"4796_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/pcan.2014.35","volume":"17","author":"A Patrikidou","year":"2014","unstructured":"Patrikidou A, Loriot Y, Eymard JC, Albiges L, Massard C, Ileana E, et al. Who dies from prostate cancer? Prostate Cancer Prostatic Dis. 2014;17:348\u201352. https:\/\/doi.org\/10.1038\/pcan.2014.35.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4796_CR3","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"4796_CR4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354.","journal-title":"Lancet."},{"key":"4796_CR5","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983\u201392.","journal-title":"Lancet Oncol"},{"key":"4796_CR6","doi-asserted-by":"crossref","unstructured":"Ryan C, Smith MR, Fizazi K, Miller K, Mulders PF, Sternberg C, et al. Final overall survival analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate in metastatic castration-resistant prostate Cancer patients without prior chemotherapy. Ann Oncol. 2014;25.","DOI":"10.1093\/annonc\/mdu336.1"},{"key":"4796_CR7","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"4796_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","volume":"71","author":"TM Beer","year":"2017","unstructured":"Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71:151\u20134. https:\/\/doi.org\/10.1016\/j.eururo.2016.07.032.","journal-title":"Eur Urol"},{"key":"4796_CR9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"key":"4796_CR10","doi-asserted-by":"publisher","first-page":"e16096","DOI":"10.1200\/jco.2013.31.15_suppl.e16096","volume":"31","author":"N Chaumard-Billotey","year":"2013","unstructured":"Chaumard-Billotey N, Chabaud S, Boyle HJ, Favier B, Devaux Y, Droz J-P, et al. Impact of news drugs in the median overall survival of patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2013;31:e16096\u2013e. https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.e16096.","journal-title":"J Clin Oncol"},{"key":"4796_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1200\/JCO.2018.36.6_suppl.323","volume":"36","author":"O Caffo","year":"2018","unstructured":"Caffo O, Kinspergher S, Maines F, Macrini S, Veccia A. Impact of new agents (NAs) on survival of metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A single-Institution retrospective analysis. J Clin Oncol. 2018;36:323. https:\/\/doi.org\/10.1200\/JCO.2018.36.6_suppl.323.","journal-title":"J Clin Oncol"},{"key":"4796_CR12","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41391-018-0121-2","volume":"22","author":"E Francini","year":"2019","unstructured":"Francini E, Gray KP, Shaw GK, Evan CP, Hamid AA, Perry CE, et al. Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer Prostatic Dis. 2019;22:420\u20137. https:\/\/doi.org\/10.1038\/s41391-018-0121-2.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4796_CR13","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.2147\/DDDT.S122417","volume":"11","author":"E Deshayes","year":"2017","unstructured":"Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, Cachin F, Hennequin C, et al. Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017;11:2643\u201351. https:\/\/doi.org\/10.2147\/DDDT.S122417.","journal-title":"Drug Des Devel Ther"},{"key":"4796_CR14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","volume":"20","author":"M Smith","year":"2019","unstructured":"Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:408\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(18)30860-X.","journal-title":"Lancet Oncol"},{"key":"4796_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/1097-0142(19880101)61:1<195","volume":"61","author":"MS Soloway","year":"1988","unstructured":"Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61:195\u2013202. https:\/\/doi.org\/10.1002\/1097-0142(19880101)61:1<195.","journal-title":"Cancer"},{"key":"4796_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2019.04.007","volume":"114","author":"MJ Morris","year":"2019","unstructured":"Morris MJ, Loriot Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, et al. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation\/randomised phase 2a trial. Eur J Cancer. 2019;114:107\u201316. https:\/\/doi.org\/10.1016\/j.ejca.2019.04.007.","journal-title":"Eur J Cancer"},{"key":"4796_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.22034\/APJCP.2018.19.1.21","volume":"19","author":"T Satoh","year":"2018","unstructured":"Satoh T, Ledesma D, Yoshihara N. The economic burden of metastatic castration resistant prostate cancer and skeletal related events in Japanese university hospitals. Asian Pac J Cancer Prev. 2018;19:21\u20136. https:\/\/doi.org\/10.22034\/APJCP.2018.19.1.21.","journal-title":"Asian Pac J Cancer Prev"},{"key":"4796_CR18","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/cncr.20955","volume":"103","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615\u201324.","journal-title":"Cancer"},{"key":"4796_CR19","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897\u2013903. https:\/\/doi.org\/10.1200\/JCO.2004.00.6908.","journal-title":"J Clin Oncol"},{"key":"4796_CR20","doi-asserted-by":"publisher","first-page":"12520","DOI":"10.18632\/oncotarget.3724","volume":"6","author":"M Iuliani","year":"2015","unstructured":"Iuliani M, Pantano F, Buttigliero C, Fioramonti M, Bertaglia V, Vincenzi B, et al. Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. Oncotarget. 2015;6:12520\u20138. https:\/\/doi.org\/10.18632\/oncotarget.3724.","journal-title":"Oncotarget"},{"key":"4796_CR21","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1158\/1078-0432.CCR-16-2955","volume":"23","author":"MI Suominen","year":"2017","unstructured":"Suominen MI, Fagerlund KM, Rissanen JP, Konkol YM, Morko JP, Peng Z, et al. Radium-223 inhibits osseous prostate Cancer growth by dual targeting of Cancer cells and bone microenvironment in mouse models. Clin Cancer Res. 2017;23:4335\u201346. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2955.","journal-title":"Clin Cancer Res"},{"key":"4796_CR22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2307\/3570636","volume":"10","author":"RE Rowland","year":"1959","unstructured":"Rowland RE, Marshall JH, Jowsey J. Radium in human bone: the microradiographic appearance. Radiat Res. 1959;10:323\u201334.","journal-title":"Radiat Res"},{"key":"4796_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S1470-2045(18)30929-X","volume":"20","author":"DE Spratt","year":"2019","unstructured":"Spratt DE. Combination therapies in prostate cancer: proceed with caution. Lancet Oncol. 2019;20:321\u20133. https:\/\/doi.org\/10.1016\/S1470-2045(18)30929-X.","journal-title":"Lancet Oncol"},{"key":"4796_CR24","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1016\/S1470-2045(19)30226-8","volume":"20","author":"MC Cursano","year":"2019","unstructured":"Cursano MC, Santini D, Iuliani M, Paganelli G, De Giorgi U. Early use of abiraterone and radium-223 in metastatic prostate cancer. Lancet Oncol. 2019;20:e228. https:\/\/doi.org\/10.1016\/S1470-2045(19)30226-8.","journal-title":"Lancet Oncol"},{"key":"4796_CR25","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1200\/JCO.2019.37.15_suppl.5007","volume":"37","author":"BF Tombal","year":"2019","unstructured":"Tombal BF, Loriot Y, Saad F, McDermott RS, Elliott T, Rodriguez-Vida A, et al. Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333\/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis. J Clin Oncol. 2019;37:5007. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.5007.","journal-title":"J Clin Oncol"},{"key":"4796_CR26","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"15","author":"P Hoskin","year":"2014","unstructured":"Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15:1397\u2013406.","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04796-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-020-04796-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04796-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T23:04:55Z","timestamp":1617577495000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-020-04796-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,5]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["4796"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-04796-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,5]]},"assertion":[{"value":"1 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Caffo received honoraria as advisor and speaker for Astellas, Astra Zeneca, Bayer, Janssen, Pfizer and Sanofi.Baldari received honoraria as advisor and speaker for Bayer and Sanofi.Monari received honoraria as advisor and speaker for Bayer.Tucci received honoraria as speaker for Astellas, Bayer, Janssen and Sanofi.Fanti received honoraria from Bayer; Blue Earth Diagnostics; Sanofi; Research Funding from Blue Earth Diagnostics; Travel, Accommodations, Expenses from Bayer; Blue Earth Diagnostics; Sanofi The other authors have no disclosures to be declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Due to observational retrospective nature of the study the informed consent was not need.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}